当前位置: 首页 >> 检索结果
1201. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis.
作者: Victor Sapena.;Marco Enea.;Ferran Torres.;Ciro Celsa.;Jose Rios.;Giacomo Emanuele Maria Rizzo.;Pierre Nahon.;Zoe Mariño.;Ryosuke Tateishi.;Tatsuya Minami.;Angelo Sangiovanni.;Xavier Forns.;Hidenori Toyoda.;Stefano Brillanti.;Fabio Conti.;Elisabetta Degasperi.;Ming-Lung Yu.;Pei-Chien Tsai.;Kevin Jean.;Mohamed El Kassas.;Hend Ibrahim Shousha.;Ashraf Omar.;Claudio Zavaglia.;Hiroko Nagata.;Mina Nakagawa.;Yasuhiro Asahina.;Amit G Singal.;Caitlin Murphy.;Mohamed Kohla.;Chiara Masetti.;Jean-François Dufour.;Nicolas Merchante.;Luisa Cavalletto.;Liliana Lc Chemello.;Stanislas Pol.;Javier Crespo.;Jose Luis Calleja.;Rosanna Villani.;Gaetano Serviddio.;Alberto Zanetto.;Sarah Shalaby.;Francesco Paolo Russo.;Rob Bielen.;Franco Trevisani.;Calogero Cammà.;Jordi Bruix.;Giuseppe Cabibbo.;Maria Reig.
来源: Gut. 2022年71卷3期593-604页
The benefit of direct-acting antivirals (DAAs) against HCV following successful treatment of hepatocellular carcinoma (HCC) remains controversial. This meta-analysis of individual patient data assessed HCC recurrence risk following DAA administration.
1202. Utility of mismatch repair protein expression screening via an endoscopic ultrasound assessment of treatment-naive pancreas ductal adenocarcinoma.
作者: Ana Garcia Garcia de Paredes.;Rondell P Graham.;Michael J Levy.;Robert R McWilliams.;Elizabeth Rajan.;Lizhi Zhang.;Ferga C Gleeson.
来源: Gut. 2022年71卷1期219-221页 1205. Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment.
作者: Man-Fung Yuen.;Danny Ka-Ho Wong.;Thomas Schluep.;Ching-Lung Lai.;Carlo Ferrari.;Stephen Locarnini.;Regina Cheuk-Lam Lo.;Robert G Gish.;James Hamilton.;Christine I Wooddell.;Lung Yi Mak.;Bruce D Given.
来源: Gut. 2022年71卷4期789-797页
We examined the serological, virological (in serum and liver) and histological profiles in chronic hepatitis B virus (HBV) patients during and after completion of multiple dose (MD) ARC-520.
1206. Chronic small intestinal dysmotility presenting as jejunal diverticulosis with refractory malabsorption: role for partial enterectomy?
作者: Lucas Wauters.;Mathias Clarysse.;Ina Jochmans.;Diethard Monbaliu.;Laurens J Ceulemans.;Astrid Verbiest.;Marc Miserez.;Nathalie Lauwers.;Wendy Nys.;Nelle Pauwels.;Martin Hiele.;Jacques Pirenne.;Tim Vanuytsel.
来源: Gut. 2022年71卷1期218-219页 1207. Novel pathomechanism for spontaneous bacterial peritonitis: disruption of cell junctions by cellular and bacterial proteases.
作者: Marika Haderer.;Philip Neubert.;Eva Rinner.;Annika Scholtis.;Lucile Broncy.;Heidi Gschwendtner.;Arne Kandulski.;Vlad Pavel.;Alexander Mehrl.;Christoph Brochhausen.;Sophie Schlosser.;Karsten Gülow.;Claudia Kunst.;Martina Müller.
来源: Gut. 2022年71卷3期580-592页
Spontaneous bacterial peritonitis (SBP) is a life-threatening complication of liver cirrhosis with a 1-year mortality of 66%. Bacterial translocation (BT) from the intestine to the mesenteric lymph nodes is crucial for the pathogenesis of SBP.
1208. Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity.
作者: Tu-Xiong Huang.;Xiang-Yu Tan.;Hui-Si Huang.;Yu-Ting Li.;Bei-Lei Liu.;Kai-Sheng Liu.;Xinchun Chen.;Zhe Chen.;Xin-Yuan Guan.;Chang Zou.;Li Fu.
来源: Gut. 2022年71卷2期333-344页
Solid tumours respond poorly to immune checkpoint inhibitor (ICI) therapies. One major therapeutic obstacle is the immunosuppressive tumour microenvironment (TME). Cancer-associated fibroblasts (CAFs) are a key component of the TME and negatively regulate antitumour T-cell response. Here, we aimed to uncover the mechanism underlying CAFs-mediated tumour immune evasion and to develop novel therapeutic strategies targeting CAFs for enhancing ICI efficacy in oesophageal squamous cell carcinoma (OSCC) and colorectal cancer (CRC).
1209. Gut microbiota modulates COPD pathogenesis: role of anti-inflammatory Parabacteroides goldsteinii lipopolysaccharide.
作者: Hsin-Chih Lai.;Tzu-Lung Lin.;Ting-Wen Chen.;Yu-Lun Kuo.;Chih-Jung Chang.;Tsung-Ru Wu.;Ching-Chung Shu.;Ying-Huang Tsai.;Simon Swift.;Chia-Chen Lu.
来源: Gut. 2022年71卷2期309-321页
Chronic obstructive pulmonary disease (COPD) is a global disease characterised by chronic obstruction of lung airflow interfering with normal breathing. Although the microbiota of respiratory tract is established to be associated with COPD, the causality of gut microbiota in COPD development is not yet established. We aimed to address the connection between gut microbiota composition and lung COPD development, and characterise bacteria and their derived active components for COPD amelioration.
1210. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies.
作者: Alessandro Mantovani.;Graziana Petracca.;Giorgia Beatrice.;Alessandro Csermely.;Herbert Tilg.;Christopher D Byrne.;Giovanni Targher.
来源: Gut. 2022年71卷4期778-788页
We performed a meta-analysis of observational studies to quantify the magnitude of the association between non-alcoholic fatty liver disease (NAFLD) and risk of extrahepatic cancers.
1212. Lactobacillus rhamnosus GG induces cGAS/STING- dependent type I interferon and improves response to immune checkpoint blockade.
作者: Wei Si.;Hua Liang.;Jason Bugno.;Qi Xu.;Xingchen Ding.;Kaiting Yang.;Yanbin Fu.;Ralph R Weichselbaum.;Xin Zhao.;Liangliang Wang.
来源: Gut. 2022年71卷3期521-533页
Our goals were to evaluate the antitumour efficacy of Lactobacillus rhamnosus GG (LGG) in combination with immune checkpoint blockade (ICB) immunotherapies on tumour growth and to investigate the underlying mechanisms.
1213. ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4.
作者: Tianxing Zhou.;Jing Liu.;Yongjie Xie.;Shuai Yuan.;Yu Guo.;Weiwei Bai.;Kaili Zhao.;Wenna Jiang.;Hongwei Wang.;Haotian Wang.;Tiansuo Zhao.;Chongbiao Huang.;Song Gao.;Xiuchao Wang.;Shengyu Yang.;Jihui Hao.
来源: Gut. 2022年71卷2期357-371页
The crosstalk between cancer stem cells (CSCs) and their niche is required for the maintenance of stem cell-like phenotypes of CSCs. Here, we identified E26 transformation-specific homologous factor (EHF) as a key molecule in decreasing the sensitivity of pancreatic cancer (PC) cells to CSCs' niche stimulus. We also explored a therapeutic strategy to restore the expression of EHF.
1217. Senolytic elimination of Cox2-expressing senescent cells inhibits the growth of premalignant pancreatic lesions.
作者: Dror Kolodkin-Gal.;Lior Roitman.;Yossi Ovadya.;Narmen Azazmeh.;Benjamin Assouline.;Yehuda Schlesinger.;Rachel Kalifa.;Shaul Horwitz.;Yonatan Khalatnik.;Anna Hochner-Ger.;Ashraf Imam.;Jonathan Abraham Demma.;Eitan Winter.;Hadar Benyamini.;Sharona Elgavish.;Areej As Khatib.;Karen Meir.;Karine Atlan.;Eli Pikarsky.;Oren Parnas.;Yuval Dor.;Gideon Zamir.;Ittai Ben-Porath.;Valery Krizhanovsky.
来源: Gut. 2022年71卷2期345-355页
Cellular senescence limits tumourigenesis by blocking the proliferation of premalignant cells. Additionally, however, senescent cells can exert paracrine effects influencing tumour growth. Senescent cells are present in premalignant pancreatic intraepithelial neoplasia (PanIN) lesions, yet their effects on the disease are poorly characterised. It is currently unknown whether senolytic drugs, aimed at eliminating senescent cells from lesions, could be beneficial in blocking tumour development.
1218. Letter to the editor regarding: Multicentre, prospective, randomised study comparing the diagnostic yield of colon capsule endoscopy versus CT colonography in a screening population (the TOPAZ study).
作者: Firas Ahmed.;Cecelia Brewington.;Kevin Jeffrey Chang.;Courtney Coursey Moreno.;Marc Gollub.;Judy Yee.
来源: Gut. 2022年71卷1期214-215页 1219. Genomic evolution and diverse models of systemic metastases in colorectal cancer.
作者: Hai-Ning Chen.;Yang Shu.;Fei Liao.;Xue Liao.;Hongying Zhang.;Yun Qin.;Zhu Wang.;Maochao Luo.;Qiuluo Liu.;Zhinan Xue.;Minyuan Cao.;Shouyue Zhang.;Wei-Han Zhang.;Qianqian Hou.;Xuyang Xia.;Han Luo.;Yan Zhang.;Lie Yang.;Jian-Kun Hu.;Xianghui Fu.;Bo Liu.;Hongbo Hu.;Canhua Huang.;Yong Peng.;Wei Cheng.;Lunzhi Dai.;Li Yang.;Wei Zhang.;Biao Dong.;Yuan Li.;Yuquan Wei.;Heng Xu.;Zong-Guang Zhou.
来源: Gut. 2022年71卷2期322-332页
The systemic spread of colorectal cancer (CRC) is dominated by the portal system and exhibits diverse patterns of metastasis without systematical genomic investigation. Here, we evaluated the genomic evolution of CRC with multiorgan metastases using multiregion sequencing.
|